Adage Capital Management, L.P., together with managing members Robert Atchinson and Phillip Gross, filed a Schedule 13G on November 12, 2026, reporting beneficial ownership of 4,190,023 shares of common stock in Camp4 Therapeutics Corporation, a Delaware-incorporated biotherapeutics company headquartered in Watertown, Massachusetts.

Key Highlights

  • Three reporting persons: Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross each report identical aggregate beneficial ownership of 4,190,023 shares.
  • Ownership percentage: The 4,190,023 shares represent 6.68% of Camp4 Therapeutics' common stock, par value $0.0001 per share (CUSIP 13463J101).
  • Shared voting and dispositive power: All 4,190,023 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Shares outstanding basis: The 6.68% figure is calculated against 62,753,200 shares outstanding as of August 12, 2026, as reported in Camp4's quarterly report for the period ended June 30, 2026.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.
  • Ordinary course certification: The filing states the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Adage Capital's Reported Position in Camp4 Therapeutics

According to the Schedule 13G filed with the SEC, Adage Capital Management, L.P. ("ACM"), a Delaware limited partnership, serves as investment manager of Adage Capital Partners, L.P. ("ACP"), which directly holds the reported shares of Camp4 Therapeutics Corporation. The filing identifies ACM's principal business office as 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. Camp4 Therapeutics Corporation, the issuer, is a Delaware corporation with principal executive offices at 100 Talcott Avenue, Suite 201, Watertown, MA 02472.

The filing reports that Robert Atchinson and Phillip Gross, both United States citizens, are co-managing members of Adage Capital Advisors, L.L.C. and related general partner entities within the Adage Capital structure, giving each of them shared voting and dispositive power over the same 4,190,023 shares held directly by ACP. Neither individual holds any sole voting or sole dispositive power over the reported shares, according to the filing. Each of the three reporting persons is classified under Schedule 13G: ACM as an investment adviser and limited partnership ("IA, PN"), and Atchinson and Gross each as a holding company and individual ("HC, IN").

The percentage of class, 6.68%, is calculated by the reporting persons based on 62,753,200 shares of Camp4 Therapeutics common stock outstanding as of August 12, 2026, a figure sourced from the company's quarterly report for the period ended June 30, 2026, filed with the SEC on August 13, 2026. The filing further notes that it "should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein."

What Was Disclosed

Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross jointly disclosed a 6.68% beneficial ownership position, totaling 4,190,023 shares of Camp4 Therapeutics Corporation common stock, through a Schedule 13G filing dated November 12, 2026, with a triggering event date of September 30, 2026.